Related Experiment Videos
Measuring costs and financial benefits in randomized controlled trials
1Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, England.
American Heart Journal
|March 1, 1990
Summary
Economic assessments in clinical trials compare costs and benefits of healthcare programs. Cost-effectiveness, cost-utility, and cost-benefit analyses are key for evaluating treatments, including quality of life.
Area of Science:
- Health Economics
- Clinical Trial Analysis
- Pharmacoeconomics
Background:
- Economic assessment integrates cost-benefit analysis into clinical trials for healthcare programs.
- Evaluating different health interventions requires comparing their economic value.
Purpose of the Study:
- To discuss and exemplify three main economic evaluation types: cost-effectiveness, cost-utility, and cost-benefit analysis.
- To illustrate the measurement of direct and indirect costs with specific examples.
- To justify economic evaluation when higher costs yield greater benefits.
Main Methods:
- Description of cost-effectiveness, cost-utility, and cost-benefit analysis methodologies.
- Explanation of direct and indirect cost measurement in healthcare.
- Presentation of economic analyses for naftidrofuryl in cerebral infarction and auranofin in rheumatoid arthritis.
Main Results:
- Economic analyses provide a framework for comparing healthcare interventions.
- Naftidrofuryl for cerebral infarction and auranofin for rheumatoid arthritis serve as case studies.
- The justification for economic evaluation is linked to achieving superior benefits from more expensive treatments.
Conclusions:
- Economic evaluation is crucial for informed healthcare decision-making.
- Consideration of quality of life and health status is essential alongside clinical outcomes.
- Pharmacoeconomic studies guide resource allocation in healthcare settings.